• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

    3/4/24 4:24:14 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TVGN alert in real time by email
    SC 13G 1 tevogen13g.htm



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. )*

    Tevogen Bio Holdings Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     

     88165K101
    (CUSIP Number)
     
    February 14, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☐
    Rule 13d-1(b)
     
    ☒
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    Persons who respond to the collection of information contained
    in this form are not required to respond unless the form
    displays a currently valid OMB control number.

    CUSIP No.
    88165K101
    13G
     
     
     
    1
    NAMES OF REPORTING PERSONS
     
     
     
     
     
    Manmohan Patel
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a) ☐
     

    (b) ☐
     

    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    646,412
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    8,628,077
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    646,412
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    8,628,077
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,274,489
     
     
     
     
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     ☐

           
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.6%(1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON*
     
     
    IN
     
     
     
     

    (1)
    Calculated based on 164,614,418 shares of Common Stock outstanding as of Febuary 22, 2024 as disclosed in the Schedule 13D filed by Ryan H. Saadi on February 22, 2024.





    CUSIP No.
    88165K101
    13G
     
     

     Item 1(a)
     Name of Issuer:
     
     
     
    The name of the issuer is Tevogen Bio Holdings Inc. (the “Issuer”).
     
     
    Item 1(b)
    Address of Issuer's Principal Executive Offices:
     
     
     
    15 Independence Boulevard, Suite #410, Warren, New Jersey 07059.
     
     
    Item 2(a)
    Name of Person Filing:
     
     
     
    Manmohan Patel
     
     
    Item 2(b)
    Address of Principal Business Office or, if none, Residence:
     
     
     
    5 Jennie Court, Cedar Grove, NJ 07009
     
     
    Item 2(c)  Citizenship:
       
     
    United States 
       
    Item 2(d)
    Title of Class of Securities:
     
     
     
    Common Stock
     
     
    Item 2(e)
    CUSIP No.:
     
     
     
    88165K101
     
     
    Item 3
    If this statement is filed pursuant to §§240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
     
     (a) ☐ 
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     (b) ☐ 
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     (c) ☐ 
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     (d) ☐ 
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     (e) ☐ 
    Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
     (f) ☐ 
    Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
     (g) ☐ 
    Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
     (h) ☐ 
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     (i) ☐ 
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     (j) ☐ 
    A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
     (k) ☐ 
    Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .



    Item 4
    Ownership:


    Tevogen Bio Holdings Inc.

     
    (a)
      Amount beneficially owned: 9,274,489
     
     
    (b)
      Percent of class:  5.6%
     
     
    (c)
      Number of shares as to which such person has: 
     
     
    (i)
      Sole power to vote or direct the vote:  646,412
     
     
     
    (ii)
      Shared power to vote or direct the vote: 8,628,077
     
     
     
    (iii)
      Sole power to dispose or direct the disposition: 646,412
     
     
     
    (iv)
      Shared power to dispose or direct the disposition: 8,628,077

    Item 5
    Ownership of Five Percent or Less of a Class:
       


     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.
     
    Item 6 Ownership of More Than Five Percent on Behalf of Another Person:


     
     Not applicable.


    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
     
     
     
    Not applicable.
     
     
    Item 8
    Identification and Classification of Members of the Group:
     
     
     
    Not applicable.
     
     
    Item 9
    Notice of Dissolution of Group:
     
     
     
    Not applicable.
     
     
    Item 10
    Certification:
     
     
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date: March 4, 2024

           Manmohan Patel  
             
           /s/ Manmohan Patel  
           Manmohan Patel  

       


     
     



    Get the next $TVGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TVGN

    DatePrice TargetRatingAnalyst
    3/4/2025$10.00Buy
    D. Boral Capital
    More analyst ratings

    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

    Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing. This formalizes the binding term sheet previously announced May 10, 2024. Combined with this financing, Tevogen's efficient and innovative business model is expected to support r

    8/19/25 3:40:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

    Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (NASDAQ:TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission ("SEC

    8/19/25 12:10:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

    WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to the Opportunity Project, a Millburn, N.J.–based nonprofit dedicated to empowering individuals with brain injuries through its innovative Clubhouse model. Founded in 1993, Opportunity Project has served more than 600 individuals and their families, providing programs that foster independence, self‑esteem, and community reintegration. "This donation is a small way to express my admiration for Opportunity Project's work and its impact on so many lives," said D

    8/18/25 5:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    SEC Filings

    View All

    SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

    424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    8/14/25 5:12:55 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Tevogen Bio Holdings Inc.

    10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    8/14/25 4:45:50 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

    424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    7/10/25 9:18:41 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/13/24 4:30:24 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/7/24 4:29:51 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Tevogen Bio with a new price target

    D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

    3/4/25 8:26:08 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Saadi Ryan H. gifted 20,000 shares, decreasing direct ownership by 0.02% to 124,794,453 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    8/18/25 4:59:39 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Saadi Ryan H. was granted 8,000,000 shares, increasing direct ownership by 7% to 124,814,453 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    7/1/25 4:49:36 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Khan Sadiq was granted 200,000 shares, increasing direct ownership by 21% to 1,169,618 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    7/1/25 4:49:18 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/12/24 4:28:55 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

    SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    3/4/24 4:24:14 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Financials

    Live finance-specific insights

    View All

    Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

    Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (NASDAQ:TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission ("SEC

    8/19/25 12:10:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

    WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio's use. This arrangement, when finalized, will not dilute existing Tevogen Bio shareholders.On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment ("Series C"). The

    2/14/25 1:16:54 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

    WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payable quarterly. The Series C Preferred Stock is convertible into shares of common stock after 6 months at the election of the holder, and callable by Tevogen for redemption after 5 years at Tevogen's e

    8/22/24 9:00:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

    WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

    4/29/25 8:00:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

    WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

    4/14/25 1:53:50 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

    WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi's leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond. This announcement coincides with a significant milestone in Tevogen's growth, the appointment of David E. Banko, as Global Head of Government Affairs and Patient Access. Mr. Banko's focus will include a

    3/26/25 3:12:23 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care